Metraipolis › archive › dc_2d11a75bd2f4

A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets — Europe PMC PMID:41499692

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41499692
DOI
10.17305/bb.2026.13832
License (as archived)
solo-consultazione
Archived
2026-11-07T01:22:38.829Z
SHA-256 of the archived text
73eb4ba4bea7a896d823072a78b48823858c3d0df7a5d116b1ae11a939e9672c
Stable URL of this page
https://metraipolis.com/documento/dc_2d11a75bd2f4

How to cite

A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets — Europe PMC PMID:41499692 — Europe PMC (en), https://europepmc.org/article/MED/41499692 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2d11a75bd2f4 (Metraipolis archive dc_2d11a75bd2f4, sha256 73eb4ba4bea7a896d823072a78b48823858c3d0df7a5d116b1ae11a939e9672c)
BibTeX
@misc{dc2d11a75bd2f4,
  title = {A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets — Europe PMC PMID:41499692},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41499692},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2d11a75bd2f4; sha256 73eb4ba4bea7a896d823072a78b48823858c3d0df7a5d116b1ae11a939e9672c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41499692. Agents can read the archived copy with the MCP tool read_document.